Contract V797D6041E
Aprecia Pharmaceuticals Company · Department Of Veterans Affairs · July 8, 2016
Aprecia Pharmaceuticals Company was awarded a federal contract by Department Of Veterans Affairs on July 8, 2016 for an undisclosed amount of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 4 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on January 26, 2017. If all options are exercised, the contract could reach $25,000.
Contract details
- PIID
- V797D6041E
- Award type
- —
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- July 8, 2016
- Latest action
- January 26, 2017
Description
65IB_ TEMPORARY CONTRACT EXTENSION_ 07/15/2016 - 02/28/2017_ MDR
Modification timeline
-
January 26, 2017Mod P00009$0
-
January 10, 2017Mod P0000865IB, TEMPORARY CONTRACT EXTENSION, MDR$0
-
December 7, 2016Mod P00007PL 2017$0
-
November 21, 2016Mod P0000165IB, ADM CHG- ADMIN POC AND IFF/SALES POC CHGS$0
-
July 8, 2016Base award65 I B, DRUGS, PHARMACEUTICALS,&HEMATOLOGY RELATED PRODUCT FSS INTERIM AGREEMENT$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Petnet Solutions, Inc. | Department Of Veterans Affairs | April 1, 2026 | $387.4K |
| Eli Lilly And Company | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Exelan Pharmaceuticals Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Cardinal Health 414, Llc | Department Of Veterans Affairs | April 1, 2026 | $122.9K |
| Guardian Pharmacy Of Indianapolis Nuclear, Llc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Jubilant Draximage Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 53,729 | $99.76B |
| 2 | Pfizer Inc | 4,613 | $28.68B |
| 3 | Merck Sharp & Dohme Llc | 391 | $21.58B |
| 4 | Modernatx, Inc. | 3 | $8.20B |
| 5 | Sanofi Vaccines Us Inc. | 5,248 | $7.76B |
| 6 | Glaxosmithkline, Llc | 1,418 | $7.22B |
| 7 | Merck Sharp & Dohme Corp. | 349 | $5.33B |
| 8 | Pfizer Inc. | 3,842 | $4.83B |
| 9 | Eli Lilly And Company | 18 | $4.67B |
| 10 | Amerisourcebergen Drug Corp | 497 | $3.23B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract V797D6041E?
Contract V797D6041E is a federal contract awarded to Aprecia Pharmaceuticals Company by Department Of Veterans Affairs on July 8, 2016 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 4 times since the base award.
Who won contract V797D6041E?
Aprecia Pharmaceuticals Company won contract V797D6041E from Department Of Veterans Affairs.
How much is contract V797D6041E worth?
Contract V797D6041E has obligated $0 to date but carries a potential ceiling of $25,000 if fully funded and all options are exercised.